Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients will be approached to participate in this PAS after the HeartWare® Ventricular Assist System receives PMA approval for the indicated use as a bridge to cardiac transplantation.
Patients who participated in prior trials will be approached for this PAS as follows:
Patients who participated in prior trials who will not be approached to participate in this follow-up study include:
• Patients who have been explanted for transplant or recovery and have completed at least 6 months of follow-up (documented in the prior IDE trial).
No new patients are being screened or implanted with the HeartWare® System for this trial, it is a follow-up trial only.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HeartWare® VAS | Ventricular Assist Device (HeartWare® VAS) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| HeartWare® VAS | Device | The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival on Device | Overall survival is the probability (expressed as a percent of 100) the participant did not die within 5 years post implant via the Kaplan-Meier method. Participants that did not die were censored at the time of last follow-up or their end of study at 5 years post implant, whichever occurred first. | Implant to 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Final Patient Status | The number and percentage of participants with a given outcome (e.g., alive on device, transplant, death, etc.) as of their last follow up or end of study, whichever occurred first. | Implant to 5 years |
| Re-hospitalizations |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The patient population consists of patients who were at risk of death from refractory, advanced heart failure and implanted with a HeartWare® Ventricular Assist System under IDE G070199.
Patients must have participated as a study patient in a prior HeartWare trial under IDE G070199, and been implanted with the HeartWare® System
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University School of Medicine | Stanford | California | 94305 | United States | ||
| Washington Hospital Center |
Of the 101 enrolled subjects, 17 subjects enrolled post-transplant and were no longer on the HVAD device at the time of enrollment, leaving 84 subjects who enrolled while still on the HVAD device.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | HeartWare® VAS | Ventricular Assist Device (HeartWare® VAS) HeartWare® VAS: The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Sep 4, 2013 | Dec 19, 2018 |
Not provided
Not provided
Not provided
Not provided
|
A summary of the number of re-hospitalizations per participant from enrollment into HW-PAS-03 throughout their participation in the study.
| Enrollment into HW-PAS-03 to 5 years |
| Number of Participants Experiencing Any Adverse Event Per Intermacs Definition | Number of participants with an Intermacs adverse event, per the Intermacs definitions. An adverse event is any untoward medical occurrence, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the medical device. | Enrollment into HW-PAS-03 to 5 years |
| Health Status Change Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) | Health Status change as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score. The KCCQ is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (e.g., better functioning, fewer symptoms, better quality of life). The Overall Summary Score is calculated as the mean of the Physical Limitation, Total Symptom, Quality of Life and Social Limitation scores. A positive change in score from baseline indicates an improvement. | Change from baseline to 5 years |
| Health Status Change Measured by EuroQol EQ-5D (Version 5L) | The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worse imaginable health state) to 100 (best imaginable health state). | Enrollment to 5 years |
| Change in Functional Status Measured by New York Heart Association (NYHA) Class | Change in Functional status, as measured by New York Heart Association (NYHA) class. There are 4 levels of NYHA: I (Mild): No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea. II (Mild): Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. III (Moderate): Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. IV (Severe): Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased. Improvement is defined as moving from a higher numerical NYHA level to a lower numerical NYHA level (e.g., IV to III). | Change from baseline to 5 years |
| Change in Functional Status Measured by 6-minute Walk | Change in functional status, as measured by 6-minute walk test. A positive change in score from baseline indicates an improvement. | Change from baseline to 5 years |
| Washington D.C. |
| District of Columbia |
| 20010 |
| United States |
| University of Florida - Gainesville | Gainesville | Florida | 32610 | United States |
| University of Miami / Jackson Memorial Hospital | Miami | Florida | 33136 | United States |
| The Emory Clinic Inc. | Atlanta | Georgia | 30322 | United States |
| Northwestern Memorial Hospital | Chicago | Illinois | 60611 | United States |
| University of Chicago | Chicago | Illinois | 60637 | United States |
| Advocate Christ Medical Center | Oak Lawn | Illinois | 60453 | United States |
| IU Health Methodist | Indianapolis | Indiana | 46202 | United States |
| Jewish Hospital - Rudd Heart and Lung Institute | Louisville | Kentucky | 40202 | United States |
| Tufts Medical Center | Boston | Massachusetts | 02111 | United States |
| University of Michigan Hospital | Ann Arbor | Michigan | 48109 | United States |
| Henry Ford Hospital | Detroit | Michigan | 48202 | United States |
| University of Minnesota | Minneapolis | Minnesota | 55455 | United States |
| Washington University / Barnes Jewish Hospital | St Louis | Missouri | 63110 | United States |
| Montefiore Medical Center | The Bronx | New York | 10467 | United States |
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | United States |
| Ohio State University Medical Center | Columbus | Ohio | 43210 | United States |
| Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | United States |
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | United States |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | United States |
| University of Texas - South Western | Dallas | Texas | 75390 | United States |
| Texas Heart Institute | Houston | Texas | 77030 | United States |
| Northwest Cardiothoracic &Transplant Surgeons | Spokane | Washington | 99204 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
All enrolled subjects are included.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | HeartWare® VAS | Ventricular Assist Device (HeartWare® VAS) HeartWare® VAS: The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Age at enrollment into HW-PAS-03 | Mean | Standard Deviation | years |
| |||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
| |||||||||||||||||||||||
| Enrollment Characteristics | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Overall Survival on Device | Overall survival is the probability (expressed as a percent of 100) the participant did not die within 5 years post implant via the Kaplan-Meier method. Participants that did not die were censored at the time of last follow-up or their end of study at 5 years post implant, whichever occurred first. | All enrolled subjects are included | Posted | Number | Percent Probability of Survival | Implant to 5 years |
|
|
| ||||||||||||||||||||||||||
| Secondary | Final Patient Status | The number and percentage of participants with a given outcome (e.g., alive on device, transplant, death, etc.) as of their last follow up or end of study, whichever occurred first. | All enrolled subjects are included. | Posted | Count of Participants | Participants | Implant to 5 years |
|
| |||||||||||||||||||||||||||
| Secondary | Re-hospitalizations | A summary of the number of re-hospitalizations per participant from enrollment into HW-PAS-03 throughout their participation in the study. | Participants who enrolled into the trial on device are included. | Posted | Mean | Standard Deviation | Re-hospitalizations | Enrollment into HW-PAS-03 to 5 years |
|
| ||||||||||||||||||||||||||
| Secondary | Number of Participants Experiencing Any Adverse Event Per Intermacs Definition | Number of participants with an Intermacs adverse event, per the Intermacs definitions. An adverse event is any untoward medical occurrence, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the medical device. | Participants who enrolled into the trial on device are included. | Posted | Count of Participants | Participants | Enrollment into HW-PAS-03 to 5 years |
|
| |||||||||||||||||||||||||||
| Secondary | Health Status Change Measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) | Health Status change as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score. The KCCQ is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (e.g., better functioning, fewer symptoms, better quality of life). The Overall Summary Score is calculated as the mean of the Physical Limitation, Total Symptom, Quality of Life and Social Limitation scores. A positive change in score from baseline indicates an improvement. | Participants who enrolled into the trial on device are included. Participants also had to reach the Month 60 visit and complete both the baseline and Month 60 assessments to be analyzed. | Posted | Mean | Standard Deviation | score on a scale | Change from baseline to 5 years |
| |||||||||||||||||||||||||||
| Secondary | Health Status Change Measured by EuroQol EQ-5D (Version 5L) | The EuroQol-5D (version 5L) is a brief self-administered, validated instrument consisting of 2 parts. The second part consists of the EQ-5D general health status as measured by a visual analog scale (EQ-5D VAS). EQ-5D VAS measures the participant's self-rated health status on a scale from 0 (worse imaginable health state) to 100 (best imaginable health state). | Participants who enrolled into the trial on device are included. Participants also had to reach the Month 60 visit complete the assessment to be analyzed. | Posted | Mean | Standard Deviation | score on a scale | Enrollment to 5 years |
|
| ||||||||||||||||||||||||||
| Secondary | Change in Functional Status Measured by New York Heart Association (NYHA) Class | Change in Functional status, as measured by New York Heart Association (NYHA) class. There are 4 levels of NYHA: I (Mild): No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea. II (Mild): Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. III (Moderate): Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. IV (Severe): Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased. Improvement is defined as moving from a higher numerical NYHA level to a lower numerical NYHA level (e.g., IV to III). | Participants who enrolled into the trial on device were included. Participants also had to reach the Month 60 visit and complete the assessment to be analyzed. | Posted | Count of Participants | Participants | Change from baseline to 5 years |
|
| |||||||||||||||||||||||||||
| Secondary | Change in Functional Status Measured by 6-minute Walk | Change in functional status, as measured by 6-minute walk test. A positive change in score from baseline indicates an improvement. | Participants who enrolled into the trial on device are included. Subjects also had to reach the Month 60 visit and complete the assessment or indicate Not Completed to be analyzed at both the baseline and Month 60 visits. If the subject did not complete the assessment, a value of 0 was imputed. | Posted | Mean | Standard Deviation | Meters | Change from baseline to 5 years |
|
|
The adverse events are summarized from the date of enrollment through 5 years while on the originally implanted device. Only participants who enrolled into the trial on device are included.
The Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) adverse event definitions are geared towards subjects who have a mechanical circulatory support device. Subjects who enrolled into the trial post-transplant (off device) (N=17) did not have any adverse events collected during the trial.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | HeartWare® VAS | Ventricular Assist Device (HeartWare® VAS) HeartWare® VAS: The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use. | 34 | 101 | 62 | 84 | 10 | 84 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Major Bleeding | Blood and lymphatic system disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Cardiac Arrhythmia | Cardiac disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Device Malfunction | Product Issues | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Hemolysis | Blood and lymphatic system disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Hepatic Dysfunction | Hepatobiliary disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Hypertension | Cardiac disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Major Infection | Infections and infestations | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Myocardial Infarction | Cardiac disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Neurological Dysfunction | Nervous system disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Pericardial Fluid Collection | Cardiac disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Psychiatric Episode | Psychiatric disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Renal Dysfunction | Renal and urinary disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Right Heart Failure | Cardiac disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Arterial Non-CNS Thromboembolism | Vascular disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Venous Thromboembolism | Vascular disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Wound Dehiscence | Skin and subcutaneous tissue disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Other Intermacs | General disorders | Intermacs, Ver. 3.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Device Malfunction | Product Issues | Intermacs, Ver. 3.0 | Systematic Assessment |
| |
| Major Infection | Infections and infestations | Intermacs, Ver. 3.0 | Systematic Assessment |
|
In most cases, the contract allows the principal investigator to publish their data after the release of the multi-center publication (or one year after the conclusion of the study if no multi-center publication is submitted) following the sponsor review for (a) disclosure of confidential information, and (b) information that would impair the sponsor's ability to obtain patent protection.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Thomas Vassiliades, MD - VP MCS Clinical/Medical Affairs | Medtronic | +15085321956 | thomas.a.vassiliades@medtronic.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Aug 8, 2017 | Dec 19, 2018 | SAP_001.pdf |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| Unknown or Not Reported |
|
| Black or African American |
|
| Native Hawaiian or Other Pacific Islander |
|
| White |
|
| Other |
|
|
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
| Counts |
|---|
| Participants |
|
|
|